Article Information
PubMed
Published By
History
- Received December 20, 2016
- Revision received February 9, 2017
- Accepted February 13, 2017
- Published online February 17, 2017.
Copyright & Usage
Copyright © 2017 Sinclair et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Author Information
- D. Sinclair1,
- R. Featherstone1,
- M. Naschek1,
- J. Nam1,
- A. Du1,
- S. Wright1,
- K. Pance1,
- O. Melnychenko1,
- R. Weger1,
- S. Akuzawa2,
- M. Matsumoto2 and
- S. J. Siegel1
- 1Translational Neuroscience Program Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
- 2Neuroscience Research Unit, DDR, Astellas Pharma Inc., Tsukuba-Shi, Ibaraki 305-8585, Japan
- Correspondence should be addressed to either of the following: Steven J Siegel, Department of Psychiatry and Behavioral Science, University of Southern California, 2250 Alcazar St, Ste 2200, Los Angeles, CA 90033. E-mail: siegels{at}usc.edu; or Duncan Sinclair, Wicking Centre, University of Tasmania, Private Bag 143, Hobart, TAS 7001, Australia. E-mail: duncan.sinclair{at}utas.edu.au.
Author contributions
Author contributions: D.S., R.F., S.A., M.M., and S.J.S. designed research; D.S., R.F., M.N., J.N., A.D., S.W., K.P., O.M., and R.W. performed research; D.S., R.F., M.N., J.N., A.D., S.W., K.P., O.M., R.W., and S.J.S. analyzed data; D.S., R.F., and S.J.S. wrote the paper.
Disclosures
SJS is a consultant to, and receives grant support from, Astellas Pharma Inc., Zynerba Pharmaceuticals, and Boehringer Ingleheim. SA and MM are full-time employees of Astellas Pharma Inc. All other authors declare no competing financial interests.
Department of Health | National Health and Medical Research Council (NHMRC) [APP1072878]; Astellas Pharma (Astellas).
Funding
Department of Health | National Health and Medical Research Council (NHMRC)
501100000925; APP1072878Astellas Pharma (Astellas)
501100004948
Other Version
- You are viewing the most recent version of this article.
- previous version (February 17, 2017).
Article usage
In this issue
GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Fmr1 Knockout Mouse Model of Fragile X Syndrome
